Why Is SGHT Stock Rising Today? Sight Sciences Climbs After FDA Clearance for OMNI Ultra

Sight Sciences (SGHT) shares rose 12.94% in pre-market trading on Wednesday after the U.S. Food and Drug Administration granted 510(k) clearance for the company's OMNI Ultra Surgical System.

What Changed On The Regulatory Front?

The FDA clearance, announced on August 4, clears the OMNI Ultra Surgical System for use in minimally invasive glaucoma surgery. The device is the first FDA-cleared MIGS system designed for circumferential canaloplasty in a single pass.

The OMNI Ultra has an enhanced ergonomic design, improved cannula tip geometry, and a refined mechanism for delivering viscoelastic during canaloplasty procedures. Sight Sciences plans a U.S. commercial launch in the fourth quarter of 2026.

Why Is This Important For Sight Sciences?

The clearance gives Sight Sciences a differentiated product in the growing MIGS market. The legacy OMNI system has been used in more than 200,000 procedures globally, giving the company an established base of surgeon familiarity to build on. The "first mover" designation for single-pass circumferential canaloplasty could help the company strengthen its competitive position as the MIGS category continues to draw adoption among ophthalmic surgeons.

Shares rose 12.94% in pre-market trading, reflecting investor optimism around the regulatory milestone. Pre-market volumes are typically thinner, which can amplify price moves — regular-session trading will offer a clearer read on institutional reaction to the news.

What Should Investors Watch Next?

The pre-market move may not fully hold through the regular session. Beyond near-term trading, commercial execution risk remains a factor — the Q4 2026 launch timeline means revenue contribution from the new device is still quarters away. The MIGS market is also competitive, with multiple device makers targeting the same glaucoma patient population.

The Q4 2026 commercial launch will be the next major milestone after the regular session's reaction. Early surgeon adoption and training uptake will be key indicators of the product's commercial trajectory. Any competitive response from other MIGS device makers could also shape the stock's path in the months ahead.